Trial Profile
Naloxegol for Opioid-Related Gastroparesis: A Double-Blind Study With an Open Label Extension
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2020
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Gastroparesis
- Focus Therapeutic Use
- 25 Aug 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 01 Feb 2019 Planned End Date changed from 1 Mar 2020 to 30 Jan 2020.
- 01 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 30 Jan 2020.